. Such drugs are usually tested in rats with chemically induced mammary tumours; these are generally both oestrogen and prolactin dependent in female rats (Rogers, 1983) . Removal of the oestrogen source causes regression of existing tumours and prevets the occurrence of further mammany tumours (Rogers, 1983 (Mantel, 1963; Peto, 1974; Dinse, 1985).
in the treatment of human breast cancer, and has shown activity against advanced breast cancer in women (Raats et al., 1992) with minimal effects on aldosterone (Demers et al., 1990) and glucocorticoid secretion at daily doses (1-2 mg day ') producing near-maximal suppression of oestrogens (Santen et al., 1989) . At higher doses (8 mg day-') fadrozole inhibits basal aldosterone sretion (Demers et al., 1990) and at 16 mg day-' bhlts the plasma corisol response to ACTH but does not alter basal urinary cortisol secretion (Santen et al., 1989) .
Currently an oestrogen receptor antagonist, tamoxifen, is the most commonly used pharmacological treatment in women with hormone-dependent breast cancer (Banting et al., 1989) . Such drugs are usually tested in rats with chemically induced mammary tumours; these are generally both oestrogen and prolactin dependent in female rats (Rogers, 1983) . Removal of the oestrogen source causes regression of existing tumours and prevets the occurrence of further mammany tumours (Rogers, 1983) . The oestrogen source may be removed surgically by ovariectomy (Rogers, 1983) , or pharmacologically by an aromatase inhibitor that prevents the conversion of aromatisable androgens to oestrogens (Steele et al., 1987; Schieweck et al., 1988) . Fadrozole hydrochloride, [4] [5] 6, 7, benzonitrile monohydrochloride (CGS 16949A), is a potent and selective non-steroidal inhibitor of aromatase.
Fadrozole hydrochloride has already been shown to cause regression of mammary tumours induced by 7,12-dimethylbenz(a)anthracene (DMBA) in intact female Sprague-Dawley rats, with a corresponding reduction in oestradiol levels to two-thirds those of controls (Schieweck et al., 1988 (Mantel, 1963; Peto, 1974; Dinse, 1985) . (Table II) . At these same doses there was an increased incidence of focal hyperplasia of the pars distalis of the pituitary. Treated females had a significantly lower incidence (P = 0.019) of liver tumours (hepatocellular adenomas and carcinomas) than controls (Table II) . Male rats treated with fadrozole hydrochloride also had significantly fewer (P = 0.013) hepatocellular tumours (10/60, 8/60, 5/60 and 4/60 in rats treated with 0, 0.05, 0.25 and 1.25 mg kg', day-' respectively).
Resds
Fadrozole hydrochloride treatment increased the incidence of several non-neoplastic lesions in female rats (Table HII) . Ovarian stromal hyperplasia was present in females at all doses. Ovarian hyalinisation, uterine atrophy, pyelonephritis, and cystitis (inflammation, epithelial hyperplasia and haemorrhage) were increased at 0.25 and 1.25 mg kg-day-'. Grossly visible urinary calculi were present in six rats treated with 0.25 or 1.25mgkg-' day-' fadrozole hydrochloride. (Schieweck et al., 1988; Houjou et al., 1993) . The treated female rats exhibited pronounced dose-related increases in both food consumption and body weight, so the reduced incidence of tumours is not related to a reduced caloric intake, which has been demonstrated to reduce the incidence of tumours in rats (Keenan et al., 1992 androgens (Hojo and Wada, 1991; lino et al., 1991) , but these increases are modest and insufficient to prevent the increase in serum gonadotrophins that results from the decrease in circulating oestradiol (Hojo and Wada, 1991; Houjou et al., 1993) . The incidence of spontaneous mammary tumours in male rats is markedly lower than in females, and the lack of an effect of fadrozole hydrochloride on their incidence may sugget that they are not oestrogen dependent Although rare, mammary tumours in human males are associated with oestrogen-related disorders and have been found to be associated with a high incidence of oestrogen receptor expression (Bezwoda et al., 1987; Fox et al., 1992) .
The incidence of pituitary adenomas and carcinomas in the female rats treated with 0.25 or 1.25mgkg-1 day-' is not only lower than that in the controls in this study, but also well below the lowest incidence in our historical data on female rats (McMartin et al., 1992) . While we are not aware of reports documenting oestrogen deprivation as a means of reducing the incidence of, or promoting the regression of, spontaneous adenomas and carcinomas of the pars distalis of the pituitary in rats, the reduced inidence in female rats treated with fadrozole hydrochloride is conistent with the observation that pituitary pars distalis adenomas can be induced in rats by oestrogen treatment (Osamura, 1983) . The oestrogen-induced tumours resemble the naturaly occurring tumours in that they also produce prolactin (Osamura, 1983) .
Prolactin production by pituitary tumours in control rats and those on lower doses of fadrozole hydrochloride may also be a stimulating factor in mammary tumour development (Rogers, 1983) . Fadrozole hydrochloride completely suppresses serum prolactin in rats at doses 1.0mg kg-' day-' or greater, but suppression is incomplete at lower doses (Houjou et al., 1993) . The higher incidence of focal hyperplasia of the pars disalis in rats treated with the highest dose of fadrozole hydrochloride most likely reflects a delay in the progression from focal hyperplasia to adenoma, a common age-related proliferative lesion of female Sprague-Dawley rats
The lower incidence of liver tumours in male and female rats administered fadrozole hydrochloride is in sharp contrast to findings with tamoxifen, which is currently used to treat advanced breast cancer in post-menopausal women. Tamoxifen, an oestrogen antagonist with weak residual oestrogenic activity, has been found to elicit hepatocellular neoplasms as early as 3-6 months after administration to female Sprague-Dawley rats (Williams et al., 1993) . Tamoxifen exerts both oestrogenic and anti-oestrogenic effects depending on the species and the tissue. In rats and humans, antioestrogens have been shown to exhibit oestrogen-like effects on lipid metabolism (Lmener and Jordan, 1990 ), a predominantly liver-mediated response. The dichotomy of the arcinogenic response of the liver to fadrozole hydrochloride, a slctive aromataw inhibitor devoid of oestrogenic activity (Steele et al., 1987) , as compared with tamoxifen, an antioestrogen with weak oestrogenic activity (Lener and Jordan, 1990) , may be related to expression of oestrogenic activity in the liver of the rat by tamoxifen. It will be of interest to see if other steroidal and non-steroidal aromatase inhibitors also reduce the incidence of liver tumours in rats.
The incdence of several non-neoplastic, proliferative lesions was increased in female rats adnmistered fadrozole hydrochloride. These increases are consistent with the pharmacological action of the compound, i.e. inhibition of oestrogen formation. Ovarian stromal hyperplasia and hyalinisation were anticipated to result from interference with negative feedback by oestrogen to the pituitary, resulting in high levels of gonadotrophic hormones (Ganong, 1987 Although there was a marked increase in ovarian weights and in the incidence of enlarged, firm ovaries in treated rats, there was no increase in the incidence of ovarian tumours in treated rats.
The increased incidence of ascending urinary tract infections (pyelonephritis and cystitis) is presumably secondary to the lack of oestrogen, which leads to genitourinary atrophy and a rise in vaginal pH, in turn resulting in an inreased susceptibility to the colonisation of the tract by bacteria (London and Hammond, 1987) . Large numbers of oestrogen receptors are present in the vagina, vulva, urethra and trigone of the bladduer (London and Hammond, 1987) .
In conclusion, fadrozole hydrochloride is highly effective in reducing the incidence of spontaneous mammary tumours in rats, and represents the first therapeutic agent to have an inhibitory effect on spontaneous mammary tumours in rats. Inhibition of spontaneous mouse mammary tumours by tamoxifen has been reported (Jordan et al., 1991 
